Monday, 26 October 2020


Lupin launches generic Clobex Lotion in the US

06 February 2018 | News

Clobetasol Propionate Lotion 0.05% had annual sales of approximately USD 12.6 million in the US

Pharma major Lupin has announced the launch of its Clobetasol Propionate Lotion 0.05% having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Clobetasol Propionate Lotion 0.05% is the generic equivalent of Galderma Labs’ Clobex® lotion. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, in patients 18 years of age or older.

Clobetasol Propionate Lotion 0.05% had annual sales of approximately USD 12.6 million in the US (IQVIA MAT December 2017).

Lupin is currently developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2nd largest Indian pharmaceutical company by global revenues (March 31st, 2017, Bloomberg); 6th largest generic pharmaceutical player in Japan and 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account